Kenya National Cancer Control Programme (NCCP) FHIR Implementation Guide, published by Digital Health Agency (DHA), Kenya. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/IntelliSOFT-Consulting/nccpFHIRIG/ and changes regularly. See the Directory of published versions
| Active as of 2026-06-04 |
@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
# - resource -------------------------------------------------------------------
a fhir:CodeSystem ;
fhir:nodeRole fhir:treeRoot ;
fhir:id [ fhir:v "treatment-course-codes-cs"] ; #
fhir:language [ fhir:v "en"] ; #
fhir:text [
fhir:status [ fhir:v "generated" ] ;
fhir:div [ fhir:v "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem treatment-course-codes-cs</b></p><a name=\"treatment-course-codes-cs\"> </a><a name=\"hctreatment-course-codes-cs\"> </a><p>This case-sensitive code system <code>https://nshr-uat.sha.go.ke/fhir/CodeSystem/treatment-course-codes-cs</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">AC<a name=\"treatment-course-codes-cs-AC\"> </a></td><td>AC</td><td>Doxorubicin + Cyclophosphamide</td></tr><tr><td style=\"white-space:nowrap\">AC-T<a name=\"treatment-course-codes-cs-AC-T\"> </a></td><td>AC-T</td><td>Doxorubicin + Cyclophosphamide followed by Paclitaxel</td></tr><tr><td style=\"white-space:nowrap\">AC-TH<a name=\"treatment-course-codes-cs-AC-TH\"> </a></td><td>AC-TH</td><td>AC-T with Trastuzumab (HER2+)</td></tr><tr><td style=\"white-space:nowrap\">CMF<a name=\"treatment-course-codes-cs-CMF\"> </a></td><td>CMF</td><td>Cyclophosphamide + Methotrexate + 5-Fluorouracil</td></tr><tr><td style=\"white-space:nowrap\">FAC<a name=\"treatment-course-codes-cs-FAC\"> </a></td><td>FAC</td><td>5-Fluorouracil + Doxorubicin + Cyclophosphamide</td></tr><tr><td style=\"white-space:nowrap\">FEC<a name=\"treatment-course-codes-cs-FEC\"> </a></td><td>FEC</td><td>5-Fluorouracil + Epirubicin + Cyclophosphamide</td></tr><tr><td style=\"white-space:nowrap\">TC<a name=\"treatment-course-codes-cs-TC\"> </a></td><td>TC</td><td>Docetaxel + Cyclophosphamide</td></tr><tr><td style=\"white-space:nowrap\">FOLFOX<a name=\"treatment-course-codes-cs-FOLFOX\"> </a></td><td>FOLFOX</td><td>5-Fluorouracil + Leucovorin + Oxaliplatin</td></tr><tr><td style=\"white-space:nowrap\">FOLFIRI<a name=\"treatment-course-codes-cs-FOLFIRI\"> </a></td><td>FOLFIRI</td><td>5-Fluorouracil + Leucovorin + Irinotecan</td></tr><tr><td style=\"white-space:nowrap\">CAPOX<a name=\"treatment-course-codes-cs-CAPOX\"> </a></td><td>CAPOX/XELOX</td><td>Capecitabine + Oxaliplatin</td></tr><tr><td style=\"white-space:nowrap\">BEP<a name=\"treatment-course-codes-cs-BEP\"> </a></td><td>BEP</td><td>Bleomycin + Etoposide + Cisplatin</td></tr><tr><td style=\"white-space:nowrap\">CHOP<a name=\"treatment-course-codes-cs-CHOP\"> </a></td><td>CHOP</td><td>Cyclophosphamide + Doxorubicin + Vincristine + Prednisone</td></tr><tr><td style=\"white-space:nowrap\">R-CHOP<a name=\"treatment-course-codes-cs-R-CHOP\"> </a></td><td>R-CHOP</td><td>Rituximab + CHOP</td></tr><tr><td style=\"white-space:nowrap\">ABVD<a name=\"treatment-course-codes-cs-ABVD\"> </a></td><td>ABVD</td><td>Doxorubicin + Bleomycin + Vinblastine + Dacarbazine</td></tr><tr><td style=\"white-space:nowrap\">GEM-CIS<a name=\"treatment-course-codes-cs-GEM-CIS\"> </a></td><td>Gem-Cis</td><td>Gemcitabine + Cisplatin</td></tr><tr><td style=\"white-space:nowrap\">GEM-CARBO<a name=\"treatment-course-codes-cs-GEM-CARBO\"> </a></td><td>Gem-Carbo</td><td>Gemcitabine + Carboplatin</td></tr><tr><td style=\"white-space:nowrap\">PACLITAXEL-CARBO<a name=\"treatment-course-codes-cs-PACLITAXEL-CARBO\"> </a></td><td>Paclitaxel-Carboplatin</td><td>Paclitaxel + Carboplatin</td></tr><tr><td style=\"white-space:nowrap\">CISPLATIN-5FU<a name=\"treatment-course-codes-cs-CISPLATIN-5FU\"> </a></td><td>Cisplatin-5FU</td><td>Cisplatin + 5-Fluorouracil</td></tr><tr><td style=\"white-space:nowrap\">SINGLE-CAPECITABINE<a name=\"treatment-course-codes-cs-SINGLE-CAPECITABINE\"> </a></td><td>Single-agent Capecitabine</td><td>Capecitabine monotherapy</td></tr><tr><td style=\"white-space:nowrap\">SINGLE-PACLITAXEL<a name=\"treatment-course-codes-cs-SINGLE-PACLITAXEL\"> </a></td><td>Single-agent Paclitaxel</td><td>Paclitaxel monotherapy</td></tr><tr><td style=\"white-space:nowrap\">SINGLE-GEMCITABINE<a name=\"treatment-course-codes-cs-SINGLE-GEMCITABINE\"> </a></td><td>Single-agent Gemcitabine</td><td>Gemcitabine monotherapy</td></tr><tr><td style=\"white-space:nowrap\">MVAC<a name=\"treatment-course-codes-cs-MVAC\"> </a></td><td>MVAC</td><td>Methotrexate + Vinblastine + Doxorubicin + Cisplatin</td></tr><tr><td style=\"white-space:nowrap\">OTHER<a name=\"treatment-course-codes-cs-OTHER\"> </a></td><td>Other</td><td>Regimen not listed; specify in free text.</td></tr></table></div>"^^rdf:XMLLiteral ]
] ; #
fhir:url [
fhir:v "https://nshr-uat.sha.go.ke/fhir/CodeSystem/treatment-course-codes-cs"^^xsd:anyURI ;
fhir:l <https://nshr-uat.sha.go.ke/fhir/CodeSystem/treatment-course-codes-cs>
] ; #
fhir:version [ fhir:v "0.1.0"] ; #
fhir:name [ fhir:v "TreatmentCourseCodesCS"] ; #
fhir:title [ fhir:v "Kenya Treatment Course (Regimen) Code System"] ; #
fhir:status [ fhir:v "active"] ; #
fhir:experimental [ fhir:v false] ; #
fhir:date [ fhir:v "2026-06-04T14:49:30+00:00"^^xsd:dateTime] ; #
fhir:publisher [ fhir:v "Digital Health Agency (DHA), Kenya"] ; #
fhir:contact ( [
fhir:name [ fhir:v "Digital Health Agency (DHA), Kenya" ] ;
( fhir:telecom [
fhir:system [ fhir:v "url" ] ;
fhir:value [ fhir:v "https://dha.go.ke" ] ] [
fhir:system [ fhir:v "email" ] ;
fhir:value [ fhir:v "info@dha.go.ke" ] ] )
] [
fhir:name [ fhir:v "Digital Health Agency Kenya – FHIR Team" ] ;
( fhir:telecom [
fhir:system [ fhir:v "email" ] ;
fhir:value [ fhir:v "info@dha.go.ke" ] ;
fhir:use [ fhir:v "work" ] ] [
fhir:system [ fhir:v "url" ] ;
fhir:value [ fhir:v "https://dha.go.ke" ] ;
fhir:use [ fhir:v "work" ] ] )
] ) ; #
fhir:description [ fhir:v "Standard oncology chemotherapy regimen codes used in Kenya."] ; #
fhir:jurisdiction ( [
( fhir:coding [
fhir:system [
fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ;
fhir:l <urn:iso:std:iso:3166> ] ;
fhir:code [ fhir:v "KE" ] ;
fhir:display [ fhir:v "Kenya" ] ] )
] ) ; #
fhir:caseSensitive [ fhir:v true] ; #
fhir:content [ fhir:v "complete"] ; #
fhir:count [ fhir:v "23"^^xsd:nonNegativeInteger] ; #
fhir:concept ( [
fhir:code [ fhir:v "AC" ] ;
fhir:display [ fhir:v "AC" ] ;
fhir:definition [ fhir:v "Doxorubicin + Cyclophosphamide" ]
] [
fhir:code [ fhir:v "AC-T" ] ;
fhir:display [ fhir:v "AC-T" ] ;
fhir:definition [ fhir:v "Doxorubicin + Cyclophosphamide followed by Paclitaxel" ]
] [
fhir:code [ fhir:v "AC-TH" ] ;
fhir:display [ fhir:v "AC-TH" ] ;
fhir:definition [ fhir:v "AC-T with Trastuzumab (HER2+)" ]
] [
fhir:code [ fhir:v "CMF" ] ;
fhir:display [ fhir:v "CMF" ] ;
fhir:definition [ fhir:v "Cyclophosphamide + Methotrexate + 5-Fluorouracil" ]
] [
fhir:code [ fhir:v "FAC" ] ;
fhir:display [ fhir:v "FAC" ] ;
fhir:definition [ fhir:v "5-Fluorouracil + Doxorubicin + Cyclophosphamide" ]
] [
fhir:code [ fhir:v "FEC" ] ;
fhir:display [ fhir:v "FEC" ] ;
fhir:definition [ fhir:v "5-Fluorouracil + Epirubicin + Cyclophosphamide" ]
] [
fhir:code [ fhir:v "TC" ] ;
fhir:display [ fhir:v "TC" ] ;
fhir:definition [ fhir:v "Docetaxel + Cyclophosphamide" ]
] [
fhir:code [ fhir:v "FOLFOX" ] ;
fhir:display [ fhir:v "FOLFOX" ] ;
fhir:definition [ fhir:v "5-Fluorouracil + Leucovorin + Oxaliplatin" ]
] [
fhir:code [ fhir:v "FOLFIRI" ] ;
fhir:display [ fhir:v "FOLFIRI" ] ;
fhir:definition [ fhir:v "5-Fluorouracil + Leucovorin + Irinotecan" ]
] [
fhir:code [ fhir:v "CAPOX" ] ;
fhir:display [ fhir:v "CAPOX/XELOX" ] ;
fhir:definition [ fhir:v "Capecitabine + Oxaliplatin" ]
] [
fhir:code [ fhir:v "BEP" ] ;
fhir:display [ fhir:v "BEP" ] ;
fhir:definition [ fhir:v "Bleomycin + Etoposide + Cisplatin" ]
] [
fhir:code [ fhir:v "CHOP" ] ;
fhir:display [ fhir:v "CHOP" ] ;
fhir:definition [ fhir:v "Cyclophosphamide + Doxorubicin + Vincristine + Prednisone" ]
] [
fhir:code [ fhir:v "R-CHOP" ] ;
fhir:display [ fhir:v "R-CHOP" ] ;
fhir:definition [ fhir:v "Rituximab + CHOP" ]
] [
fhir:code [ fhir:v "ABVD" ] ;
fhir:display [ fhir:v "ABVD" ] ;
fhir:definition [ fhir:v "Doxorubicin + Bleomycin + Vinblastine + Dacarbazine" ]
] [
fhir:code [ fhir:v "GEM-CIS" ] ;
fhir:display [ fhir:v "Gem-Cis" ] ;
fhir:definition [ fhir:v "Gemcitabine + Cisplatin" ]
] [
fhir:code [ fhir:v "GEM-CARBO" ] ;
fhir:display [ fhir:v "Gem-Carbo" ] ;
fhir:definition [ fhir:v "Gemcitabine + Carboplatin" ]
] [
fhir:code [ fhir:v "PACLITAXEL-CARBO" ] ;
fhir:display [ fhir:v "Paclitaxel-Carboplatin" ] ;
fhir:definition [ fhir:v "Paclitaxel + Carboplatin" ]
] [
fhir:code [ fhir:v "CISPLATIN-5FU" ] ;
fhir:display [ fhir:v "Cisplatin-5FU" ] ;
fhir:definition [ fhir:v "Cisplatin + 5-Fluorouracil" ]
] [
fhir:code [ fhir:v "SINGLE-CAPECITABINE" ] ;
fhir:display [ fhir:v "Single-agent Capecitabine" ] ;
fhir:definition [ fhir:v "Capecitabine monotherapy" ]
] [
fhir:code [ fhir:v "SINGLE-PACLITAXEL" ] ;
fhir:display [ fhir:v "Single-agent Paclitaxel" ] ;
fhir:definition [ fhir:v "Paclitaxel monotherapy" ]
] [
fhir:code [ fhir:v "SINGLE-GEMCITABINE" ] ;
fhir:display [ fhir:v "Single-agent Gemcitabine" ] ;
fhir:definition [ fhir:v "Gemcitabine monotherapy" ]
] [
fhir:code [ fhir:v "MVAC" ] ;
fhir:display [ fhir:v "MVAC" ] ;
fhir:definition [ fhir:v "Methotrexate + Vinblastine + Doxorubicin + Cisplatin" ]
] [
fhir:code [ fhir:v "OTHER" ] ;
fhir:display [ fhir:v "Other" ] ;
fhir:definition [ fhir:v "Regimen not listed; specify in free text." ]
] ) . #
IG © 2026+ Digital Health Agency (DHA), Kenya.
Package fhir.ke.nccp#0.1.0 based on FHIR 4.0.1.
Generated
2026-06-04
Links: Table of Contents |
QA Report